FDA Bans the Use of Red No. 3 in Food and Ingested Drugs

Husch Blackwell LLP
Contact

On January 16, the U.S. Food and Drug Administration (FDA) announced that it is revoking the authorization for use of FD&C Red No. 3 in food (including dietary supplements) and ingested drugs. The dye is commonly used in beverages, candies, and other foods and drugs for its appealing red color.

The FDA has based its decision on the Delaney Clause, which prohibits the approval of any food or color additive found to induce cancer in humans or animals. In its announcement, the FDA recognized that Red No. 3 is not shown to cause cancer in humans, but the studies linking the dye to the development of cancer in rats are enough to require the ban under the Delaney Clause. The ban applies to domestic products as well as products manufactured abroad and imported into the United States.

Since the FDA received a petition to ban Red No. 3 for use in food in 2022, California passed legislation to prohibit the sale of foods with Red No. 3, and lawmakers in 10 other states introduced similar legislation.

This decision extends a previous ban from 1990 which prohibited the use of Red No. 3 in cosmetics and topical drugs. At that time, the FDA denied a petition for permanent authorization, citing data demonstrating that Red No. 3 caused cancer in rats. Use of Red No. 3 will now be prohibited in food, topical and ingested drugs, and cosmetics.

The deadline for manufacturers to reformulate products will be January 15, 2027 for food and January 18, 2028 for drugs.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Husch Blackwell LLP

Written by:

Husch Blackwell LLP
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Husch Blackwell LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide